PURPOSE: To determine the distribution of tumor-associated macrophages (TAMs) during retinoblastoma tumor development, examine the contribution of bone marrow-derived TAMs in retinoblastoma tumors, and evaluate the supportive role of TAMs in tumor growth in a transgenic retinoblastoma mouse model. METHODS: The time course of macrophage infiltration in transgenic retinoblastoma tumors was assessed by immunohistochemistry at different time points in tumorigenesis. The origin of TAMs in transgenic retinoblastoma tumors was determined by transplanting 10(7) bone marrow cells from green fluorescent protein (GFP)-positive 16-week-old mice into age-matched, irradiated LH(BETA)T(AG) mice via tail vein injections. Macrophage depletion was performed by subconjunctival (SC) delivery of liposomal clodronate. RESULTS: The density of TAMs increased from 4 to 12 weeks of age in mice with small to medium tumors (P = 0.037) and remained stable in the later stages of disease (i.e., 16 weeks old with large tumors; P = 0.20). In 16-week-old mice, 38% (2.5 +/- 3.2 cells per 400x high-power field) of TAMs were GFP-positive, bone marrow-derived macrophages. Total TAM depletion was associated with a significant decrease in the expression levels of MMP-9 (P = 0.014) and mature vessels (P < 0.001) and a nonsignificant decrease in the density of neovessels (P = 0.94). The density of M2-polarized TAMs did not change significantly after TAM depletion (P = 0.68). After M1-polarized TAM depletion, the tumor burden increased (P = 0.056). CONCLUSIONS: This work extends understanding of the complex role that macrophages play in retinoblastoma. Macrophage modulation in the tumor microenvironment is a critical factor in retinoblastoma tumor progression.
PURPOSE: To determine the distribution of tumor-associated macrophages (TAMs) during retinoblastoma tumor development, examine the contribution of bone marrow-derived TAMs in retinoblastoma tumors, and evaluate the supportive role of TAMs in tumor growth in a transgenic retinoblastomamouse model. METHODS: The time course of macrophage infiltration in transgenic retinoblastoma tumors was assessed by immunohistochemistry at different time points in tumorigenesis. The origin of TAMs in transgenic retinoblastoma tumors was determined by transplanting 10(7) bone marrow cells from green fluorescent protein (GFP)-positive 16-week-old mice into age-matched, irradiated LH(BETA)T(AG) mice via tail vein injections. Macrophage depletion was performed by subconjunctival (SC) delivery of liposomal clodronate. RESULTS: The density of TAMs increased from 4 to 12 weeks of age in mice with small to medium tumors (P = 0.037) and remained stable in the later stages of disease (i.e., 16 weeks old with large tumors; P = 0.20). In 16-week-old mice, 38% (2.5 +/- 3.2 cells per 400x high-power field) of TAMs were GFP-positive, bone marrow-derived macrophages. Total TAM depletion was associated with a significant decrease in the expression levels of MMP-9 (P = 0.014) and mature vessels (P < 0.001) and a nonsignificant decrease in the density of neovessels (P = 0.94). The density of M2-polarized TAMs did not change significantly after TAM depletion (P = 0.68). After M1-polarized TAM depletion, the tumor burden increased (P = 0.056). CONCLUSIONS: This work extends understanding of the complex role that macrophages play in retinoblastoma. Macrophage modulation in the tumor microenvironment is a critical factor in retinoblastoma tumor progression.
Authors: T P Slegers; P F Torres; L Broersma; N van Rooijen; G van Rij; R van der Gaag Journal: Invest Ophthalmol Vis Sci Date: 2000-07 Impact factor: 4.799
Authors: Tanja P A M Slegers; Gerard van der Veen; L Joep A Hermans; Lidy Broersma; Nico van Rooijen; Hendrika J Völker-Dieben; Gabriel van Rij; Ruth van der Gaag Journal: Graefes Arch Clin Exp Ophthalmol Date: 2003-04-16 Impact factor: 3.117
Authors: Tanja P A M Slegers; Ruth van der Gaag; Nico van Rooijen; Gabriel van Rij; J Wayne Streilein Journal: Curr Eye Res Date: 2003-02 Impact factor: 2.424
Authors: Sanja Pajovic; Timothy W Corson; Clarellen Spencer; Helen Dimaras; Marija Orlic-Milacic; Mellone N Marchong; Kwong-Him To; Brigitte Thériault; Mark Auspitz; Brenda L Gallie Journal: Invest Ophthalmol Vis Sci Date: 2011-09-29 Impact factor: 4.799
Authors: Yolanda Piña; Samuel K Houston; Timothy G Murray; Tulay Koru-Sengul; Christina Decatur; William K Scott; Lubov Nathanson; Jennifer Clarke; Theodore J Lampidis Journal: Clin Ophthalmol Date: 2012-05-29